Abcam, ab209962, PE Anti-PD-L1 antibody [28-8]

Size: 100µL
Anti-PD-L1 antibody [28-8] - PE conjugated (ab209962) is a rabbit recombinant monoclonal antibody detecting PD-L1 in Flow Cytometry . Suitable for Human . - Biophysical QC for unrivalled batch-batch consistency
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:28-8,
Isotype:IgG,
Conjugation:PE,
Excitation/Emission:Ex: 480;565nm, Em: 578nm,
Carrier free:No,
Reacts with:Human,
Applications:Flow CytSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.

Product details:
What is this antibody validated in?
PE Anti-PD-L1 antibody [28-8] (ab209962) is a rabbit recombinant monoclonal antibody and is validated for use in Flow Cytometry (Flow Cyt) in Human samples.
Related products
Antibody clone 28-8 is also available pre-conjugated to a variety of labels for your convenience – Anti-PD-L1 PE [28-8] (ab209962).
Other related products
We have a range of other formats of antibody clone [28-8] also available for your convenience:
ab205921
, APC -
ab206967
, Carrier free -
ab209889
, Alexa Fluor® 488 -
ab209959
, Alexa Fluor® 647 -
ab209960
, HRP -
ab209961
, PE - ab209962, Alexa Fluor® 555 -
ab213358
, Alexa Fluor® 568 -
ab213359
, Alexa Fluor® 594 -
ab213360
, FITC -
ab224027
, Carrier free -
ab228413
, Carrier free -
ab278010
, Alexa Fluor® 647 - ab303724, Carrier free - ab307495, Biotin -
ab322788
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein A, Storage buffer-pH: 7.4Preservative: 0.02% Sodium azideConstituents: PBS, 1% BSA, Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C, Aliquoting information-Upon delivery aliquot, Storage information-Do Not Freeze, Store in the dark

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
PD-L1 also known as Programmed Death-Ligand 1 or CD274 is a protein involved in immune modulation. Mechanically PD-L1 interacts with its receptors particularly PD-1 to regulate cellular immune responses. This transmembrane protein has a calculated molecular weight of approximately 33 kDa. PD-L1 is expressed on various cell types including tumor cells and immune cells such as dendritic cells macrophages and B cells. Its expression is often upregulated in response to inflammatory cytokines.
Biological function summary
PD-L1 plays a central role in immune evasion mechanisms utilized by tumors. It is not part of a larger protein complex but directly interacts with PD-1 and CD80. When PD-L1 binds to PD-1 it sends inhibitory signals leading to decreased T cell activation and proliferation allowing cancer cells to avoid immune destruction. PD-L1 expression provides a mechanism for tumors to suppress immune surveillance facilitating tumor progression.
Pathways
PD-L1 is integral to the immune checkpoint pathway which is an important regulator of immune response. The interaction between PD-L1 and PD-1 provides a mechanism for immune tolerance which is part of the broader adaptive immune system pathway. PD-L1 is related to other immune checkpoint proteins such as CTLA-4 in its function to limit autoreactivity and promote immune homeostasis.
PD-L1 is most associated with cancer particularly in tumors such as melanoma and non-small cell lung cancer. PD-L1 expression on tumor cells often correlates with poor prognosis. PD-L1 directly interacts with PD-1 in these cancers a target for immunotherapies such as checkpoint inhibitors which aim to block this interaction and restore immune activity against tumors. PD-L1 involvement extends to autoimmune disorders where altered expression can impact tolerance and lead to immune-related tissue damage.